BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 17136470)

  • 21. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
    J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases.
    Badiee S; Franc BL; Webb EM; Chu B; Hawkins RA; Coakley F; Singer L
    AJR Am J Roentgenol; 2008 Nov; 191(5):1436-9. PubMed ID: 18941082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging and treatment of patients with colorectal liver metastases in the Netherlands: a survey.
    Bipat S; van Leeuwen MS; Ijzermans JN; Bossuyt PM; Greve JW; Stoker J
    Neth J Med; 2006 May; 64(5):147-51. PubMed ID: 16702613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation.
    Prytz H; Keiding S; Björnsson E; Broomé U; Almer S; Castedal M; Munk OL;
    Hepatology; 2006 Dec; 44(6):1572-80. PubMed ID: 17133469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning?
    Adie S; Yip C; Chu F; Morris DL
    ANZ J Surg; 2009 May; 79(5):358-61. PubMed ID: 19566517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.
    Boykin KN; Zibari GB; Lilien DL; McMillan RW; Aultman DF; McDonald JC
    Am Surg; 1999 Dec; 65(12):1183-5. PubMed ID: 10597072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
    Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
    J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography.
    Abbadi RA; Sadat U; Jah A; Praseedom RK; Jamieson NV; Cheow HK; Whitley S; Ford HE; Wilson CB; Harper SJ; Huguet EL
    J Surg Oncol; 2014 Sep; 110(3):313-9. PubMed ID: 24737685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET.
    García Vicente AM; Domínguez Ferreras E; Sánchez Pérez V; Poblete García VM; Villa Guzmán JC; Jiménez Aragón F; Pineda Pineda MD; Molino Trinidad C; Soriano Castrejón Á
    Eur J Radiol; 2013 Jun; 82(6):e255-61. PubMed ID: 23414715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
    Fong Y; Saldinger PF; Akhurst T; Macapinlac H; Yeung H; Finn RD; Cohen A; Kemeny N; Blumgart LH; Larson SM
    Am J Surg; 1999 Oct; 178(4):282-7. PubMed ID: 10587184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET.
    Rydzewski B; Dehdashti F; Gordon BA; Teefey SA; Strasberg SM; Siegel BA
    AJR Am J Roentgenol; 2002 Feb; 178(2):353-8. PubMed ID: 11804891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation).
    Elias D; Sideris L; Pocard M; de Baere T; Dromain C; Lassau N; Lasser P
    Ann Surg Oncol; 2005 Apr; 12(4):298-302. PubMed ID: 15827682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of FDG-PET in the selection of patients with colorectal liver metastases.
    Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
    Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory gated and prolonged acquisition 18F-FDG PET improve preoperative assessment of colorectal liver metastases.
    Revheim ME; Haugvik SP; Johnsrud K; Mathisen Ø; Fjeld JG; Skretting A
    Acta Radiol; 2015 Apr; 56(4):397-403. PubMed ID: 24682406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of diagnostic imaging modalities for colorectal liver metastases.
    Bonanni L; de'Liguori Carino N; Deshpande R; Ammori BJ; Sherlock DJ; Valle JW; Tam E; O'Reilly DA
    Eur J Surg Oncol; 2014 May; 40(5):545-550. PubMed ID: 24491289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
    Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
    Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.
    Ruers TJ; Wiering B; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Krabbe PF; Oyen WJ
    J Nucl Med; 2009 Jul; 50(7):1036-41. PubMed ID: 19525451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings.
    Lubezky N; Metser U; Geva R; Nakache R; Shmueli E; Klausner JM; Even-Sapir E; Figer A; Ben-Haim M
    J Gastrointest Surg; 2007 Apr; 11(4):472-8. PubMed ID: 17436132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of hepatic metastases from colorectal carcinoma with MR-superparamagnetic iron oxide.
    Vidiri A; Carpanese L; Annibale MD; Caterino M; Cosimelli M; Zeuli M; David V; Crecco M
    J Exp Clin Cancer Res; 2004 Mar; 23(1):53-60. PubMed ID: 15149151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET.
    van Laarhoven HW; de Geus-Oei LF; Wiering B; Lok J; Rijpkema M; Kaanders JH; Krabbe PF; Ruers T; Punt CJ; van der Kogel AJ; Oyen WJ; Heerschap A
    Radiology; 2005 Oct; 237(1):181-8. PubMed ID: 16183932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.